Core Viewpoint - A securities class action has been filed against MoonLake Immunotherapeutics following the announcement of poor Phase 3 trial results for its product candidate sonelokimab (SLK), leading to a significant drop in share price [1][2]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on treating skin inflammatory diseases, specifically targeting cytokines IL-17A and IL-17F [3][4]. Trial Results and Market Reaction - The Phase 3 trial results revealed that only one of the two trials achieved statistical significance, with efficacy substantially lower than that of a competitor's product, BIMZELX [6]. - Following the announcement, MoonLake's share price plummeted by $55.75, approximately 90%, on September 29, 2025 [2][6]. Allegations of Misleading Information - The lawsuit claims that MoonLake misled investors regarding SLK's trial design and efficacy, asserting that the company made false statements about the advantages of SLK over BIMZELX [5][6]. - Specific allegations include misleading claims about the clinical benefits of SLK's Nanobody structure compared to traditional monoclonal antibodies [5]. Legal Proceedings - The class action lawsuit is focused on the accuracy of MoonLake's statements about SLK's trial design and data, with a class period defined from March 10, 2024, to September 29, 2025 [3][4]. - The lead plaintiff deadline for the lawsuit is set for December 15, 2025 [3].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - November 17 ...

Accessibility StatementSkip Navigation PHILADELPHIA, Nov. 17, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period"). Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025, ...

Core Points - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit for alleged misleading statements and undisclosed information related to the company's glucose monitoring products [1][2]. Allegations - The complaint alleges that DexCom made unauthorized design changes to its G6 and G7 glucose monitoring devices, which rendered them less reliable and posed health risks to users [1]. - It is claimed that the enhancements to the G7 device were overstated, and the company downplayed the severity of the issues related to the G7 devices [1]. - The allegations suggest that these actions increased the risk of regulatory scrutiny and potential legal, reputational, and financial harm to DexCom [1]. Class Action Details - The class period for the lawsuit is from January 8, 2024, to September 17, 2025, and shareholders are encouraged to register for participation by December 26, 2025 [2]. - Shareholders who register will receive updates on the case through a portfolio monitoring software [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and illegal business practices [3].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against MoonLake Immunotherapeutics, alleging that the company made materially false and misleading statements regarding its drug candidate SLK and its comparison to BIMZELX [1]. Group 1: Allegations - The lawsuit claims that during the class period from March 10, 2024, to September 29, 2025, the defendants failed to disclose that SLK and BIMZELX target the same inflammatory cytokines, IL-17A and IL-17F [1]. - It is alleged that SLK's unique Nanobody structure does not provide a clinical benefit over the traditional monoclonal structure of BIMZELX [1]. - The complaint states that the supposed increased tissue penetration of SLK does not translate to clinical efficacy, undermining the defendants' positive statements about SLK's superiority [1]. - The lawsuit argues that the defendants lacked a reasonable basis for their optimistic claims regarding SLK compared to monoclonal antibodies [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased MLTX shares during the specified class period are encouraged to register for the class action by December 15, 2025, to potentially become lead plaintiffs [2]. - Upon registration, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. - Participation in the case incurs no cost or obligation for the shareholders [2].

Accessibility StatementSkip Navigation WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statemen ...

New York, New York--(Newsfile Corp. - November 17, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=177687&wire=5&utm_campaign=1or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.Cann ...

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, under the case caption Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [3]. Group 3: Clinical Data and Allegations - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses and differentiation of sonelokimab from competitors [4]. - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 26, 2025, to $6.24 on September 29, 2025 [6].

Core Viewpoint - MoonLake Immunotherapeutics is facing a securities fraud class action lawsuit due to alleged misrepresentations regarding its clinical data and the efficacy of its investigational drug sonelokimab [1][3][4]. Group 1: Lawsuit Details - A lawsuit has been filed against MoonLake and certain senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][3]. - Investors have until December 15, 2025, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Southern District of New York [3]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its investigational drug sonelokimab [4]. - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated a higher clinical response for patients, suggesting a competitive advantage over traditional monoclonal antibody treatments [5]. Group 3: Allegations and Impact - The lawsuit alleges that the clinical data and the Nanobody structure of sonelokimab did not provide a superior clinical benefit compared to competitors, raising doubts about the drug's regulatory approval and commercial viability [6]. - Following the announcement of disappointing results from the Phase 3 VELA trials, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share within a few days [7].

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that during the class period, the defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and has recovered hundreds of millions for investors over the years [4].